Permedicon – Unique European event for personalised medicine expands
Cologne – Will personalised medicine become a reality? Is it economically feasible? Which regulatory requirements must be met to profit from new concepts for better defining and treating disease subpopulations? What criteria will health technology assessors adopt? On 21th-22th June, Cologne will become the temporary European capital of personalised medicine. All relevant stakeholders along the value chain – from biotech and pharma companies, CROs, hospitals, regulatory authorities, health technology assessors, patient organisations, and research institutions – will meet up at PerMediCon to discuss current trends, challenges and opportunities in the emerging field of personalised medicine.“Our meeting is the only event in Europe devoted exclusively to personalised medicine,” says Dr. Christian Glasmacher, Vice President from organiser Koelnmesse. “It gathers together the entire spectrum of key players and stakeholders from the different worlds – from development, manufacure, use, authorisation and marketing of personalised medicines – in one place.” At its kick-off last year, PerMediCon attracted 300 visitors and 20 exhibitors. This year, Glasmacher expects 50 exhibitors and 500 experts to attend. The two-day event is a unique mixture of congress (with top lecturers), exhibition and truly interdisciplinary discussion forums on hot topics and pressing questions in the sector.
Meeting point for key players
The Personalized Medicines Convention (www.permedicon.com) gives an update on the perspectives of the very different stakeholders involved. Koelnmesse has invented its own format to bring the key players into discussion. Afternoons at the two-day event have been reserved for 12 interactive dicussions on current topics in “R&D innovations”, “Applications” and “General issues” (the economics of personalised medicine, requirements for the design of clinical studies, biobanking, and others). The focussed workshops start with a ten-minute lecture on the topic. This is followed by a discussion round with five experts (40 mins) and general discussion (15 mins), and ends with a summary of results. “The event aims to bring all stakeholders together in a European format,” says Glasmacher. A similar process has already occurred in the US – and keynote lecturer Edward Abrahams will be in Cologne to talk about it.